All In Biotech

Investigational drug · Phase 2

NIO752

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Progressive Supranuclear Palsy, Corticobasal Degeneration, Frontotemporal Lobar Degeneration.

Phase 2

Last checked: Nov 19, 2026Latest source record: Oct 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

5

Any phase or sponsor naming "NIO752"

First trial start

2026

Oct 23, 2026

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "NIO752", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Progressive Supranuclear Palsy
  • Corticobasal Degeneration
  • Frontotemporal Lobar Degeneration
  • Tauopathies

Largest trials

Live from ClinicalTrials.gov: studies naming "NIO752" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Progressive Supranuclear Palsy

  • TertomotideGV1001Phase 33 trials

    GemVax & Kael · Moderate to Severe Alzheimer's Disease, Mild to Moderate Alzheimer's Disease, Progressive Supranuclear Palsy

  • AMX0035Phase 32 trials

    Amylyx Pharmaceuticals Inc. · Wolfram Syndrome, Progressive Supranuclear Palsy, PSP

  • FNP-223Phase 21 trial

    Ferrer Internacional S.A. · Progressive Supranuclear Palsy

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Novartis.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.